Evaluation Of Serum Osteopontin And Growth Differential Factor-15 In Patients With Acute Myocardial Infraction

Mohammed Saeed Ali AL-Obaidy; Ameen M.  Aljuraisy

doi:10.51699/cajmns.v7i1.3094

Authors

Mohammed Saeed Ali AL-Obaidy College of health and medical techniques , University of Al maarif , Iraq.
Ameen M. Aljuraisy Kirkuk Education Directorate, Iraqi Ministry of Education, Kirkuk, Iraq.

DOI:

https://doi.org/10.51699/cajmns.v7i1.3094

Keywords:

Acute myocardial infarction, Osteopontin, Growth differential factor -15

Abstract

Background: Acute myocardial infraction (AMI), is irreversible heart muscle necrosis caused by a prolonged shortage of oxygen. The most prevalent cause of AMI is atherosclerosis . It is thought to be a component of the acute coronary syndrome . In this study Osteopontin (OPN) and Growth differential factor -15 (GDF-15) were measured in patients' with myocardial infraction and healthy control people, and the results were compared.

Materials and Methods: This study was conducted on 38 patients with myocardial infraction who attended to cardio care unit (CCU) in Al-Ramadi teaching hospital in period from August to October 2025. The results were compared with 30 healthy control subjects. About four milliliters of venous blood were collecting in gel tube from patients and controls to estimate OPN and GDF-15 by ELISA method. Furthermore, fasting blood sugar (FBS) and total cholesterol (CHO) were measured for patients and control groups.

Results: the level of OPN was significantly high in AMI patients (36.44± 25.72 ng/ml) compared to control group (1.07±0.41 ng/ml), GDF-15 was very high in patients group (431.68±132.25 ng/ml) when it compared with control group (85.89±14.64 ng/ml), furthermore FBS and CHO mean concentrations were significantly high in AMI patients (195.46±89.16 mg/dl), (167.93±53.88 mg/dl) respectively, compared with control group (FBS 97.08±13.84 mg/dl), (CHO 112.18±10.64 mg/dl).

References

A. E. Azab and A. S. I. Elsayed, “Acute Myocardial Infarction Risk Factors and Correlation of its Markers with Serum Lipids,” J Appl Biotechnol Bioeng, vol. 3, no. 4, p. 00075, 2017.

A. Long, B. Long, and A. Koyfman, “Non-traditional risk factors for atherosclerotic disease: A review for emergency physicians,” Am. J. Emerg. Med., vol. 36, no. 3, pp. 494–497, 2018.

C. E. Ugwu, S. E. Nwankwo, S. C. Meludu, and J. K. Nnodim, “Assessment of the risk of myocardial infarction among undergraduate students in a Nigerian tertiary institution,” Int. J. Healthcare Med. Sci., vol. 2, no. 11, pp. 60–65, 2016.

S. C. Smith Jr et al., “AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update,” Circulation, vol. 113, no. 19, pp. 2363–2372, 2006.

T. H. Lee and L. E. E. Goldman, “Serum enzyme assays in the diagnosis of acute myocardial infarction recommendations based on a quantitative analysis,” Ann. Intern. Med., vol. 105, no. 2, pp. 221–233, 1986.

H. A. Al-Hadi and K. A. Fox, “Cardiac markers in the early diagnosis and management of patients with acute coronary syndrome,” Sultan Qaboos Univ. Med. J., vol. 9, no. 3, p. 231, 2009.

S. Mythili and N. Malathi, “Diagnostic markers of acute myocardial infarction,” Biomed. Rep., vol. 3, no. 6, pp. 743–748, 2015.

H. D. White and D. P. Chew, “Acute myocardial infarction,” Lancet, vol. 372, no. 9638, pp. 570–584, 2008.

M. Sharma, R. San Tan, and U. R. Acharya, “A novel automated diagnostic system for classification of myocardial infarction ECG signals using an optimal biorthogonal filter bank,” Comput. Biol. Med., vol. 102, pp. 341–356, 2018.

K. X. Wang and D. T. Denhardt, “Osteopontin: role in immune regulation and stress responses,” Cytokine Growth Factor Rev., vol. 19, no. 5–6, pp. 333–345, 2008.

S. P. Sase, J. V. Ganu, and N. Nagane, “Osteopontin: a novel protein molecule,” Indian Med. Gaz., pp. 62–66, Feb. 2012.

X. Qin et al., “Cancer-associated fibroblast-derived IL-6 promotes head and neck cancer progression via the osteopontin-NF-kappa B signaling pathway,” Theranostics, vol. 8, no. 4, p. 921, 2018.

T. Ikeda, T. Shirasawa, Y. Esaki, S. Yoshiki, and K. Hirokawa, “Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta,” J. Clin. Invest., vol. 92, no. 6, pp. 2814–2820, 1993.

P. P. Nghiem et al., “Osteopontin is linked with AKT, FoxO1, and myostatin in skeletal muscle cells,” Muscle Nerve, vol. 56, no. 6, pp. 1119–1127, 2017.

S. Vianello et al., “SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells,” Hum. Mol. Genet., vol. 26, no. 17, pp. 3342–3351, 2017.

S. D. Ricardo, D. F. Franzoni, C. D. Roesener, J. M. Crisman, and J. R. Diamond, “Angiotensinogen and AT1 antisense inhibition of osteopontin translation in rat proximal tubular cells,” Am. J. Physiol.-Renal Physiol., vol. 278, no. 5, pp. F708–F716, 2000.

M. F. Young et al., “cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN),” Genomics, vol. 7, no. 4, pp. 491–502, 1990.

M. Noda and G. A. Rodan, “Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone,” J. Cell Biol., vol. 108, no. 2, pp. 713–718, 1989.

N. S. Fedarko, A. Jain, A. Karadag, M. R. Van Eman, and L. W. Fisher, “Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer,” Clin. Cancer Res., vol. 7, no. 12, pp. 4060–4066, 2001.

M. Mazzali et al., “Osteopontin—a molecule for all seasons,” QJM, vol. 95, no. 1, pp. 3–13, 2002.

C. C. Kazanecki, D. J. Uzwiak, and D. T. Denhardt, “Control of osteopontin signaling and function by post‐translational phosphorylation and protein folding,” J. Cell. Biochem., vol. 102, no. 4, pp. 912–924, 2007.

M. Scatena, L. Liaw, and C. M. Giachelli, “Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease,” Arterioscler. Thromb. Vasc. Biol., vol. 27, no. 11, pp. 2302–2309, 2007.

Z. A. Al-Obaidy and A. L. Hussein Al-Zubaidi, “Evaluation of Serum Osteopontin Level and Growth Differential Factor Growth-15 in Chronic Renal Failure,” Indian J. Public Health Res. Dev., vol. 11, no. 4, 2020.

R. Adela and S. K. Banerjee, “GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective,” J. Diabetes Res., 2015.

P. J. Emmerson, K. L. Duffin, S. Chintharlapalli, and X. Wu, “GDF15 and growth control,” Front. Physiol., vol. 9, p. 1712, 2018.

T. A. Zimmers et al., “Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury,” Shock, vol. 23, no. 6, pp. 543–548, 2005.

E. C. Hsiao et al., “Characterization of growth-differentiation factor 15, a transforming growth factor β superfamily member induced following liver injury,” Mol. Cell. Biol., vol. 20, no. 10, pp. 3742–3751, 2000.

K. C. Wollert et al., “Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome,” Circulation, vol. 116, no. 14, pp. 1540–1548, 2007.

T. Kempf et al., “The transforming growth factor-β superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury,” Circ. Res., vol. 98, no. 3, pp. 351–360, 2006.

M. Li, K. Song, X. Huang, S. Fu, and Q. Zeng, “GDF‑15 prevents LPS and D‑galactosamine‑induced inflammation and acute liver injury in mice,” Int. J. Mol. Med., vol. 42, no. 3, pp. 1756–1764, 2018.

Z. A. Al-Obaidy and A. L. Hussein Al-Zubaidi, “Evaluation of Serum Osteopontin Level and Growth Differential Factor Growth-15 in Chronic Renal Failure,” Indian J. Public Health Res. Dev., vol. 11, no. 4, 2020.

M. Li, K. Song, X. Huang, S. Fu, and Q. Zeng, “GDF‑15 prevents LPS and D‑galactosamine‑induced inflammation and acute liver injury in mice,” Int. J. Mol. Med., vol. 42, no. 3, pp. 1756–1764, 2018.

J. Jurczyluk, D. Brown, and K. K. Stanley, “Polarised secretion of cytokines in primary human microvascular endothelial cells is not dependent on N‐linked glycosylation,” Cell Biol. Int., vol. 27, no. 12, pp. 997–1003, 2003.

J. B. Welsh et al., “Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum,” Proc. Natl. Acad. Sci. USA, vol. 100, no. 6, pp. 3410–3415, 2003.

K. Unsicker, B. Spittau, and K. Krieglstein, “The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1,” Cytokine Growth Factor Rev., vol. 24, no. 4, pp. 373–384, 2013.

T. Nunohiro, N. Ashizawa, K. Graf, Y. S. Do, W. A. Hsueh, and K. Yano, “Angiotensin II promotes remodelling-related events in cardiac fibroblasts,” Heart Vessels, pp. 201–204, 1997.

P. Zahradka, “Novel role for osteopontin in cardiac fibrosis,” 2008.

T. R. Einarson, A. Acs, C. Ludwig, and U. H. Panton, “Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017,” Cardiovasc. Diabetol., vol. 17, no. 1, p. 1, 2018.

Z. S. Y. Lok and A. N. Lyle, “Osteopontin in vascular disease: friend or foe?,” Arterioscler. Thromb. Vasc. Biol., vol. 39, no. 4, pp. 613–622, 2019.

C. Ruwhof and A. van der Laarse, “Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways,” Cardiovasc. Res., vol. 47, no. 1, pp. 23–37, 2000.

X. Xu, Z. Li, and W. Gao, “Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside,” Biomarkers, vol. 16, no. 6, pp. 466–475, 2011.

T. Kempf and K. C. Wollert, “Growth differentiation factor-15: a new biomarker in cardiovascular disease,” Herz, vol. 34, no. 8, pp. 594–599, 2009.

X. Bao et al., “Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmö Diet and Cancer–Cardiovascular Cohort,” Diabetologia, vol. 62, no. 1, pp. 78–86, 2019.

K. X. Wang and D. T. Denhardt, “Osteopontin: role in immune regulation and stress responses,” Cytokine Growth Factor Rev., vol. 19, no. 5–6, pp. 333–345, 2008.

F. M. Ho et al., “High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-κB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway,” Cell. Signal., vol. 18, no. 3, pp. 391–399, 2006.

G. Daniele et al., “The potential role of the osteopontin–osteocalcin–osteoprotegerin triad in the pathogenesis of prediabetes in humans,” Acta Diabetol., vol. 55, no. 2, pp. 139–148, 2018.

D. Kwon, J. J. Yi, H. Ohrr, and S. W. Yi, “Total cholesterol and mortality from ischemic heart disease and overall cardiovascular disease in Korean adults,” Medicine, vol. 98, no. 36, 2019.

U. S. General, The health benefits of smoking cessation, Washington: Department of Health and Human Services, pp. 11–17, 1990.